Valsartan alleviates atherosclerotic lesions in pulmonary arteries of rabbits via an endothelium-dependent mechanism

References

• Doran AC, Meller N and McNamara CA. Role of smooth muscle cells in the initiation and early progression of ather-osclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 812–9.
   Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990 s. Nature 1993; 362: 801–9.
   Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115–26.
   Google Scholar
• Gomez M, Sanz-Gonzalez SM, Abu Nabah YN, Lamana A, Sanchez-Madrid F, Andres V. Atherosclerosis development in apolipoprotein E-null mice deficient for CD69. Cardiovasc Res 2009; 81: 197–205.
   Google Scholar
• Kleemann R, Zadelaar S, Kooistra T. Cytokines and ather-osclerosis: a comprehensive review of studies in mice. Cardio-vasc Res 2008; 79: 360–76.
   Google Scholar
• Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2009; 81: 370–80.
   Google Scholar
• Ohishi M, Ueda M, Rakugi H, Naruko T, Kojima A, Okamura A, Higaki J, Ogihara T. Relative localization of angiotensin-converting enzyme, chymase and angiotensin II in human coronary atherosclerotic lesions. J Hypertens 1999; 17: 547–53.
   Google Scholar
• Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95: 473–8.
   Google Scholar
• Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH and Buhler FR. Essential hyper-tension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441–9.
   Google Scholar
• Chatzizisis YS, Jonas M, Beigel R, Coskun AU, Baker AB, Stone BV, Maynard C, Gerrity RG, Daley W, Edelman ER, Feldman CL and Stone PH. Attenuation of inflammation and expansive remodeling by Valsartan alone or in combi-nation with Simvastatin in high-risk coronary atheroscle-rotic plaques. Atherosclerosis 2009; 203: 387–94.
   Google Scholar
• Li Z, Iwai M, Wu L, Liu HW, Chen R, Jinno T, Suzuki J, Tsuda M, Gao XY, Okumura M, Cui TX, Horiuchi M. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 2004; 44: 758–63.
   Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA and Califf RM. Valsartan, cap-topril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
   Google Scholar
• Fukuda D, Enomoto S, Nagai R, Sata M. Inhibition of renin-angiotensin system attenuates periadventitial inflam-mation and reduces atherosclerotic lesion formation. Biomed Pharmacother 2009; 63: 754–61.
   Google Scholar
• Rosenson RS. Modulating atherosclerosis through inhibition or blockade of angiotensin. Clin Cardiol 2003; 26: 305–311.
   Google Scholar
• Duff G L, Mc MG. Pathology of atherosclerosis. Am J Med 1951; 11: 92–108.
   Google Scholar
• Zhu BQ, Sievers RE, Isenberg WM, Smith DL, Parmley WW. Regression of atherosclerosis in cholesterol-fed rabbits:effects of fish oil and verapamil. J Am Coll Cardiol 1990; 15: 231–7.
   Google Scholar
• Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholes-terolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992; 71: 343–53.
   Google Scholar
• Schwenke D. Comparison of aorta and pulmonary artery. Circ Res 1997; 81: 346–54.
   Google Scholar
• Xu HS, Duan J, Dai S, Wu Y, Sun R, Ren J. Phytoestrogen alpha-zearalanol antagonizes oxidized LDL-induced inhibi-tion of nitric oxide production and stimulation of endothe-lin-1 release in human umbilical vein endothelial cells. Endocrine 2004; 25: 235–45.
   Google Scholar
• Berman SM, Ozkaragoz T, Noble EP, Antolin T, Sheen C, Siddarth P, Conner BT, Ritchie T. Differential associations of sex and D2 dopamine receptor (DRD2) genotype with negative affect and other substance abuse risk markers in children of alcoholics. Alcohol 2003; 30: 201–10.
   Google Scholar
• Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res 2008; 79: 14–23.
   Google Scholar
• Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Shiomi M, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T. Combined effects of an 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor and angiotensin II receptor antagonist on nitric oxide bioavailability and ath-erosclerotic change in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Hypertens Res 2008; 31: 1199–208.
   Google Scholar
• Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high-cholesterol diet. J Hypertens 2005; 23: 1879–86.
   Google Scholar
• Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, Wei YS, Cai H, Liu DP, Liang CC. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases ath-erosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008; 80: 191–9.
   Google Scholar
• Papademetriou V. The potential role of AT(1)-receptor blockade in the prevention and reversal of atherosclerosis. J Hum Hypertens 2002; 16 Suppl 3: S34–41.
   Google Scholar
• Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kubler W Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623–9.
   Google Scholar
• Tsuda M, Iwai M, Li JM, Li HS, Min IA Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005; 45: 545–51.
   Google Scholar
• Doran DE, Weiss D, Zhang Y, Griendling KK, Taylor WR. Differential effects of AT1 receptor and Ca2 + channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis 2007; 195: 39–47.
   Google Scholar
• Johnstone MT, Perez AS, Nasser I, Stewart R, Vaidya A, Al Ammary F, Schmidt B, Horowitz G, Dolgoff J, Hamilton J, Quist WC. Angiotensin receptor blockade with candesartan attenuates atherosclerosis, plaque disruption, and macro-phage accumulation within the plaque in a rabbit model. Circulation 2004; 110: 2060–5.
   Google Scholar
• Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrari° CM. Inhibition of early atherogenesis by losartan in monkeyswith diet-induced hypercholesterolemia. Circulation 2000; 101: 1586–93.
   Google Scholar
• Oubina MP, de Las Heras N, Vazquez-Perez S, Cediel E, Sanz-Rosa D, Ruilope LM, Cachofeiro V, Lahera V. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens 2002; 20: 303–10.
   Google Scholar
• Glass CK, Witztum JL. Atherosclerosis, the road ahead. Cell 2001; 104: 503–16.
   Google Scholar
• Niu XF, Smith CW, Kubes P. Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils. Circ Res 1994; 74: 1133–40.
   Google Scholar
• De Caterina R, Libby P, Peng HB, Thannickal VJ, Rajavashisth TB, Gimbrone MA, Jr, Shin WS, Liao JK. Nitric oxide decreases cytokine-induced endothelial activa-tion. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96: 60–8.
   Google Scholar
• Bousette N, Giaid A. Endothelin-1 in atherosclerosis and other vasculopathies. Can J Physiol Pharmacol 2003; 81: 578–87.
   Google Scholar
• Xu H, Duan J, Dai S, Wu Y, Sun R, Ren J. alpha-Zearalanol attenuates oxLDL-induced ET-1 gene expression, ET-1 secre-tion and redox-sensitive intracellular signaling activation in human umbilical vein endothelial cells. Toxicol Lett 2008; 179: 163–8.
   Google Scholar
• Little PJ, Ivey ME, Osman N. Endothelin-1 actions on vas-cular smooth muscle cell functions as a target for the pre-vention of atherosclerosis. Curr Vasc Pharmacol 2008; 6: 195–203.
   Google Scholar